NEW YORK, April 30 - CytRx of Los Angeles said today that it has expanded its collaboration with University of Massachusetts Medical School, signing an sponsored-research agreement as the first phases of a drug-development effort in obesity and type II diabetes.
Michael Czech, chairman of the molecular medicine, will head the research effort that will apply RNAi-directed gene silencing to fat cells for target validation.
In early April, CytRx announced that it had signed a license agreement with UMMS for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.
Interested in more on RNAi? Read GenomeWeb's weekly roundup of activity.